Vitamin D for Graves' Disease

This trial explores whether high-dose vitamin D (ergocalciferol) can help treat Graves' disease in children aged 9 to 17. It compares standard treatment with methimazole, a common medication for Graves' disease, to the same treatment plus high doses of vitamin D. The study aims to determine if this approach is feasible for a larger future study. Children recently diagnosed with Graves' disease and starting methimazole might be suitable candidates. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group, providing an opportunity to contribute to important early findings.

If you are currently taking medications that affect thyroid function or vitamin D metabolism, you will need to stop them to participate in this trial.

Research has shown that vitamin D can be beneficial for people with Graves' disease, who often have lower vitamin D levels than healthy individuals. Some studies have found that increasing vitamin D can improve thyroid function in animals with the disease.

Vitamin D is generally safe, even in higher amounts. However, monitoring for side effects, especially in children, remains important. In this trial, participants will receive high doses of vitamin D2 (ergocalciferol) alongside their regular treatment. Previous studies suggest that vitamin D, when used correctly, rarely causes serious side effects.

The trial's phase indicates that earlier research has deemed the treatment safe. Treatments typically reach this stage only after passing initial safety checks.

Researchers are excited about using high-dose Vitamin D2 (ergocalciferol) for Graves' disease because it could offer a complementary approach to standard treatments like methimazole. Unlike typical treatments that primarily focus on regulating thyroid hormone production, Vitamin D2 aims to address potential vitamin D deficiency, which might play a role in the disease's progression. By adding high doses of Vitamin D2 to the treatment plan, there's hope that it could enhance the overall effectiveness of methimazole, potentially leading to better outcomes for patients.

Research has shown that vitamin D might help manage Graves' disease. One study found that vitamin D supplements helped patients return to normal thyroid function more quickly when combined with regular antithyroid treatments. Other research has linked low vitamin D levels to a higher risk of developing Graves' disease. Additionally, vitamin D has shown benefits in animal studies of thyroid issues similar to Graves'. In this trial, participants in one arm will receive high-dose vitamin D2 (ergocalciferol) alongside methimazole, while another arm will receive methimazole with the option of low-dose vitamin D2. These studies suggest that high doses of vitamin D could be a useful addition to standard treatment for Graves' disease.¹⁶⁷⁸⁹